Results 111 to 120 of about 32,769 (202)

Erectile dysfunction in dermatology and venereology: From aetiopathogenic mechanisms to practical considerations for dermato‐venereologists

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
Multiple inflammatory, infectious and autoimmune dermato‐venereological conditions are associated with erectile dysfunction (ED) due to underlying intricate vasculogenic, neurogenic, endocrine and psychogenic mechanisms. It is recommended that practitioners screen dermatology patients for ED and associated comorbidities, provide personalized lifestyle ...
Andrei Tanasov, George‐Sorin Tiplica
wiley   +1 more source

European Guideline (EuroGuiDerm) on atopic eczema: Living update

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
The updated guideline includes a new evidence‐based recommendation for the IL‐13 inhibitor lebrikizumab. In addition, the Janus kinase inhibitors baricitinib and abrocitinib, which were initially only approved for adult patients, are now also recommended for children from the age of 2 and adolescents from the age of 12, respectively.
A. Wollenberg   +31 more
wiley   +1 more source

COVID-19 in patients with psoriasis: A Latin American case series

open access: yesJAAD International, 2021
Isabela Campo-Slebi, MD   +7 more
doaj  

Comorbidity burden in the first three years after diagnosis in patients with rheumatoid arthritis, psoriatic arthritis or spondyloarthritis: a general practice registry-based study. [PDF]

open access: yesRMD Open, 2021
Stouten V   +9 more
europepmc   +1 more source

Drug survival of IL‐23 and IL‐17 inhibitors versus other biologics for psoriasis: A British Association of Dermatologists Biologics and Immunomodulators Register cohort study

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
Psoriasis affects 2–3% of the population, with numerous biologic options complicating treatment selection. This real‐world study found IL‐23p19 inhibitors offer the longest‐lasting effectiveness and safety. Psoriatic arthritis reduced ustekinumab survival, and prior biologic use impacted persistence, especially for IL‐17 inhibitors.
Leila Motedayen Aval   +8 more
wiley   +1 more source

Correspondence to: Clinico‐sero‐pathological characteristics of anti‐Ha antisynthetase syndrome

open access: yes
Brain Pathology, EarlyView.
Marie‐Therese Holzer   +5 more
wiley   +1 more source

Evaluation of the risk of heart failure with tumour necrosis factor inhibitors: A large‐scale meta‐analysis in immune‐mediated inflammatory diseases

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
Graphical abstract summarising the results of the present systematic review and meta‐analysis on the effect of tumour necrosis factor inhibitors on the risk of heart failure in immune‐mediated inflammatory diseases. CI, confidence interval; IMID, immune‐mediated inflammatory diseases; RCT, randomised controlled trial; RR, risk ratio; TNF, tumour ...
Noémi Ágnes Galajda   +10 more
wiley   +1 more source

Ultrasonographic and power doppler parameters of nails fail to differentiate between onychodystrophy in patients with psoriasis vulgaris or psoriatic arthritis

open access: yesAdvances in Rheumatology
Background Nail involvement is frequent in patients with psoriasis (Pso) and psoriatic arthritis (PsA) and there is a relationship between nail involvement and inflammation of the enthesis.
Anber Ancel Tanaka   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy